SCHEMBL31024352

SCHEMBL31024352

CC(C)(C)OC(=O)N1CCC(OCC2CCN(C(=O)c3ccc(Cl)c(N4CCC(=O)NC4=O)c3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.45
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PDK1 Q15118 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ CHEK2 O96017 1/20 0.39
▸ CRBN Q96SW2 4/20 0.38
▸ DDB1 Q16531 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ RIN1 Q13671 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31024364 0.93 MEN1 (0.42) GPR119MEN1KMT2APDK1PDK2
SCHEMBL27124609 0.93 MEN1 (0.42) GPR119MEN1KMT2APDK1PDK2
SCHEMBL27137466 0.91 GPR119 (0.41) GPR119MEN1KMT2APDK1PDK2
SCHEMBL29892557 0.90 GPR119 (0.43) GPR119MEN1KMT2APDK1PDK2
SCHEMBL23121362 0.90 KMT2A (0.44) GPR119MEN1KMT2APDK1PDK2
SCHEMBL31024377 0.89 MEN1 (0.39) GPR119MEN1KMT2APDK1PDK2
SCHEMBL28868794 0.88 MGLL (0.40) MEN1KMT2ANPSR1
SCHEMBL23123648 0.88 CNR1 (0.43) GPR119MEN1KMT2APDK1PDK2
SCHEMBL31161308 0.88 CNR1 (0.43) GPR119MEN1KMT2APDK1PDK2
SCHEMBL26099471 0.87 MEN1 (0.52) GPR119MEN1KMT2APDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SOS1, RAC1, RSU1 GPR119 3494/4885MEN1 805/4885KMT2A 4200/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 GPR119 3124/4885MEN1 920/4885KMT2A 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback